अखिल भारतीय आयुर्विज्ञान संस्थान, रायपुर (छत्तीसगढ़)
All India Institute of Medical Sciences, Raipur (Chhattisgarh)
Tatibandh, GE Road,
Raipur-492 099 (CG)
www.aiimsraipur.edu.in

AIIMS/R/HS/Antibiotic/2018/RC Date: 01/05/2018

Corrigendum

Tender no. - AIIMS/R/HS/Antibiotic/2018/RC
CPPP Tender ID No.-2018_IMSRP_321526_1

S/N.	Page no. /Clause no. as per bid documents	Existing Entry	To be Read as
1	Page no. 14 Sr. 10, point no.3	The supply should be completed within 30 days from the date of purchase order.	The supply should be completed within 30 days from the date of purchase order and in case of NABL test report to be submitted the same should be completed within 60 days.
2	Page no. 23, Annexure – I: Note	All items should have minimum expiry of 1 year at the time of supply	All items should have minimum expiry of 1 year at the time of supply & should be provided with appropriate diluents as applicable
3	Page no. 9 Sr. 4, point no.- xvii,	WHO –GMP or cGMP as per schedule M (license no. and MFG. unit address highlighted)	WHO –GMP as per schedule M (license no. and MFG. unit address highlighted)
4	Page no. 9 Sr. 4, point no.- xviii (d)	A valid WHO-GMP or cGMP as per Schedule 'M' certificate as per requirement of the Drugs and cosmetic act and rules of Govt. of India from Competent Authority	A valid WHO-GMP as per Schedule 'M' certificate as per requirement of the Drugs and cosmetic act and rules of Govt. of India from Competent Authority
5	Page no. 10 Sr. 4, point no.- xix(e)	WHO-GMP or GMP as per Schedule 'M' certificate as per requirement of the Drugs and cosmetic act and rules of Govt. of India from Competent Authority.	WHO-GMP as per Schedule 'M' certificate as per requirement of the Drugs and cosmetic act and rules of Govt. of India from Competent Authority.
6	Page no. 11 Sr.5.1, point no.-a	Manufacturer should having valid License (issued by F.D.A) under the Drugs and Cosmetics Act, 1940 (including its amendments) and should comply with Schedule M (cGMP) of Drugs and Cosmetic Act.	Manufacturer should having valid License (issued by F.D.A) under the Drugs and Cosmetics Act, 1940 (including its amendments) and should comply with Schedule M (WHO-GMP) of Drugs and Cosmetic Act.
7	Page no. 11 Sr.5.1, point no.-b	The manufacturer should have received a valid cGMP as per revised Schedule 'M' issued by Licensing Authority or WHO-GMP inspection certificate in line with the WHO certification scheme, on pharmaceuticals being quoted. Bidder should submit a valid product wise Certificate of cGMP as per schedule "M" or WHO-GMP issued by Regulatory Authority, for each item offered. License no. and manufacturing unit address clearly highlighted on cGMP certificate.	The manufacturer should have received a valid WHO-GMP as per revised Schedule 'M' issued by Licensing Authority or WHO-GMP inspection certificate in line with the WHO certification scheme, on pharmaceuticals being quoted. Bidder should submit a valid product wise Certificate of WHO-GMP as per schedule "M" or WHO-GMP issued by Regulatory Authority, for each item offered. License no. and manufacturing unit address clearly highlighted on WHO-GMP certificate.

8	Page no. 11 Sr.5.2, point no.-c	Manufacturer must have valid License (issued by F.D.A) under the Drugs and Cosmetics Act, 1940 (including its amendments) and should comply with Schedule M (cGMP) of Drugs and Cosmetic Act.	Manufacturer must have valid License (issued by F.D.A) under the Drugs and Cosmetics Act, 1940 (including its amendments) and should comply with Schedule M (WHO-GMP) of Drugs and Cosmetic Act.
9	Page no. 12 Sr.5.2, point no.-d	The manufacturer should have received a valid cGMP as per revised Schedule 'M' issued by Licensing Authority or WHO-GMP inspection certificate in line with the WHO certification scheme, on pharmaceuticals being quoted. Bidder should submit a valid product wise Certificate of cGMP as per schedule "M" or WHO-GMP issued by Regulatory Authority, for each item offered. License no. and manufacturing unit address clearly highlighted on GMP certificate	The manufacturer should have received a valid WHO-GMP as per revised Schedule 'M' issued by Licensing Authority or WHO-GMP inspection certificate in line with the WHO certification scheme, on pharmaceuticals being quoted. Bidder should submit a valid product wise Certificate of WHO-GMP as per schedule "M" or WHO-GMP issued by Regulatory Authority, for each item offered. License no. and manufacturing unit address clearly highlighted on WHO-GMP certificate
10	As Mentioned in Tender Document	Last date of Submission of tender on 08/05/2018 at 6.00 PM and opening of tender on 10/05/2018 at 03.00 P M	Last date of Submission of tender on 14/05/2018 at 6.00 PM and opening of tender on 16/05/2018 at 11.00 AM

Remarks:-

01. All other terms and condition of tender will remain unchanged.

Rishi Gupta
Stores Officer (H)
AIIMS RAIPUR

अखिलभारतीयआयुर्विज्ञानसंस्थान, रायपुर(छत्तीसगढ़)
All India Institute of Medical Sciences, Raipur (Chhattisgarh)
Tatibandh, GE Road,
Raipur-492 099 (CG)
www.aiimsraipur.edu.in

Minutes of Pre-bid Meeting

Sub: Tender No. AIIMS/R/HS/Antibiotic/2018/RC for the supply of Drug & Medicine (Antibiotic).

Ref: Pre-bid meeting held on 10.04.2018 at Ayush PMR Building AIIMS Raipur.

The following Bidders' representative attended the pre-bid meeting:

Sr. No.	Name	Organization/Firm
1	Mr. Sanjay sachdeo	M/s Pankaj Medical Traders
2	Mr. Kamal Tanwani	M/s Surya Commercial
3	Mr. PC Gothi	M/s Chopda Enterprises

Proceeding of the pre-bid meeting is as follows:-

1. At the outset, a briefing about the scope of services and purpose of the pre-bid meeting were deliberated.
2. Thereafter, prospective bidders were requested to put up their queries related to scope and terms and conditions given in the Bidding Document.
3. The queries from prospective bidders were appropriately responded. The representatives were also requested to send their queries in writing through e-mail within 2 days.
4. The responses to queries sought from prospective bidders in writing and those asked during the meeting have been compiled.
5. The Amendments made pursuance to the Bidding Documents shall be issued separately.

Deliberation:-

S/N.	Page no. /Clause no. as per bid documents	Queries raised by firm	Recommendation/ Response
1	Page no. 14 Sr. 10, point no.3	So we are discussed with Govt. Approved LAB, as per discussion with them it is finalized that on an average 30-45 days required for test & its reporting. Manufacturing company batch wise test report is submitted with bill but Govt, approved Laboratories batch wise test report required 30-45 days. So please reply any update if done in this matter.	Suitable corrigendum to be followed
2	Page no. 14 Sr. 10, point no.5	Kindly increase the value for submission of NABL report to 1 lac from 50,000 for single molecule as mentioned in tender as cost of making NABL report is quite high.	Not agreed
3	Page no. 23, Annexure	Request to mention tentative quantity of products required to quote the competitive rates.	Not agreed
4	Page no. 23, Annexure – I: Note	All items should have minimum expiry of 1 year at the time of supply	Suitable corrigendum to be followed in this regard

5	Page no. 9 Sr. 4, point no.- xvii,	WHO –GMP or cGMP as per schedule M (license no. and MFG. unit address highlighted)	Suitable corrigendum to be followed in this regard
6	Page no. 9 Sr. 4, point no.- xviii (d)	A valid WHO-GMP or cGMP as per Schedule 'M' certificate as per requirement of the Drugs and cosmetic act and rules of Govt. of India from Competent Authority	Suitable corrigendum to be followed in this regard
7	Page no. 9/10 Sr. 4, point no.- xix(e)	WHO-GMP or GMP as per Schedule 'M' certificate as per requirement of the Drugs and cosmetic act and rules of Govt. of India from Competent Authority.	Suitable corrigendum to be followed in this regard
8	Page no. 11 Sr.5.1, point no.-a	Manufacturer should having valid License (issued by F.D.A) under the Drugs and Cosmetics Act, 1940 (including its amendments) and should comply with Schedule M (cGMP) of Drugs and Cosmetic Act.	Suitable corrigendum to be followed in this regard
9	Page no. 11 Sr.5.1, point no.-b	The manufacturer should have received a valid cGMP as per revised Schedule 'M' issued by Licensing Authority or WHO-GMP inspection certificate in line with the WHO certification scheme, on pharmaceuticals being quoted. Bidder should submit a valid product wise Certificate of cGMP as per schedule "M" or WHO-GMP issued by Regulatory Authority, for each item offered. License no. and manufacturing unit address clearly highlighted on cGMP certificate.	Suitable corrigendum to be followed in this regard
10	Page no. 11 Sr.5.1, point no.-b	Manufacturer must have valid License (issued by F.D.A) under the Drugs and Cosmetics Act, 1940 (including its amendments) and should comply with Schedule M (cGMP) of Drugs and Cosmetic Act.	Suitable corrigendum to be followed in this regard
11	Page no. 12 Sr.5.2, point no.-d	The manufacturer should have received a valid cGMP as per revised Schedule 'M' issued by Licensing Authority or WHO-GMP inspection certificate in line with the WHO certification scheme, on pharmaceuticals being quoted. Bidder should submit a valid product wise Certificate of cGMP as per schedule "M" or WHO-GMP issued by Regulatory Authority, for each item offered. License no. and manufacturing unit address clearly highlighted on GMP certificate	Suitable corrigendum to be followed in this regard

Remarks: All other terms & condition of tender will remain unchanged